- Home
- AGMH vs MEIP Comparison
AGMH vs MEIP Comparison
Compare AGMH & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- MEIP
- Stock Information
- Founded
- AGMH 2015
- MEIP 2000
- Country
- AGMH Hong Kong
- MEIP United States
- Employees
- AGMH N/A
- MEIP N/A
- Industry
- AGMH EDP Services
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- AGMH Technology
- MEIP Health Care
- Exchange
- AGMH Nasdaq
- MEIP Nasdaq
- Market Cap
- AGMH 1.8M
- MEIP 17.1M
- IPO Year
- AGMH 2018
- MEIP 2003
- Fundamental
- Price
- AGMH $0.05
- MEIP $2.15
- Analyst Decision
- AGMH
- MEIP Hold
- Analyst Count
- AGMH 0
- MEIP 2
- Target Price
- AGMH N/A
- MEIP $7.00
- AVG Volume (30 Days)
- AGMH 73.1M
- MEIP 8.4K
- Earning Date
- AGMH 04-15-2025
- MEIP 05-08-2025
- Dividend Yield
- AGMH N/A
- MEIP N/A
- EPS Growth
- AGMH N/A
- MEIP N/A
- EPS
- AGMH N/A
- MEIP N/A
- Revenue
- AGMH $64,998,081.00
- MEIP N/A
- Revenue This Year
- AGMH N/A
- MEIP N/A
- Revenue Next Year
- AGMH N/A
- MEIP N/A
- P/E Ratio
- AGMH N/A
- MEIP N/A
- Revenue Growth
- AGMH N/A
- MEIP 33.76
- 52 Week Low
- AGMH $0.04
- MEIP $2.15
- 52 Week High
- AGMH $2.19
- MEIP $4.10
- Technical
- Relative Strength Index (RSI)
- AGMH 24.28
- MEIP 27.69
- Support Level
- AGMH $0.04
- MEIP $2.28
- Resistance Level
- AGMH $0.09
- MEIP $2.35
- Average True Range (ATR)
- AGMH 0.01
- MEIP 0.07
- MACD
- AGMH 0.03
- MEIP -0.01
- Stochastic Oscillator
- AGMH 8.39
- MEIP 0.00
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an investment holding company. The company focuses on blockchain-oriented ASIC chip design; high-end crypto miner production and fintech technology software service. It generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.